Thomas Deal's questions to Scholar Rock Holding Corp (SRRK) leadership • Q2 2025
Question
Thomas Deal, on for Martin Auster at Raymond James, asked about the expected enrollment timeline for the OPAL trial in children under two and the significance of this market expansion.
Answer
President of R&D Akshay Vaishnaw confirmed OPAL enrollment will begin in Q3 2025 and that guidance on completion will follow once momentum builds. He highlighted that while important, the immediate and larger opportunity is the prevalent population of over 35,000 patients aged two and older who could benefit from apitigramab.